' Astonishing ' PFS Improvement in Metastatic HER+ Breast Cancer ' Astonishing ' PFS Improvement in Metastatic HER+ Breast Cancer

Experts hail the"astonishing" improvement in progression-free survival reported with trastuzumab deruxtecan in HER2+ metastatic breast cancer.Medscape Medical News

Source: Medscape Hematology-Oncology Headlines - September 22, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news